HUE054118T2 - Biciklusos piridin-, pirazin- és pirimidin-származékok mint PI3K béta-inhibitorok - Google Patents
Biciklusos piridin-, pirazin- és pirimidin-származékok mint PI3K béta-inhibitorokInfo
- Publication number
- HUE054118T2 HUE054118T2 HUE17732059A HUE17732059A HUE054118T2 HU E054118 T2 HUE054118 T2 HU E054118T2 HU E17732059 A HUE17732059 A HU E17732059A HU E17732059 A HUE17732059 A HU E17732059A HU E054118 T2 HUE054118 T2 HU E054118T2
- Authority
- HU
- Hungary
- Prior art keywords
- pyrazine
- pyrimidine derivatives
- beta inhibitors
- pi3k beta
- bicyclic pyridine
- Prior art date
Links
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 title 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 title 1
- 125000002619 bicyclic group Chemical group 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 title 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title 1
- 150000003230 pyrimidines Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16174715 | 2016-06-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE054118T2 true HUE054118T2 (hu) | 2021-08-30 |
Family
ID=56132835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE17732059A HUE054118T2 (hu) | 2016-06-16 | 2017-06-15 | Biciklusos piridin-, pirazin- és pirimidin-származékok mint PI3K béta-inhibitorok |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10894793B2 (hu) |
| EP (1) | EP3472160B1 (hu) |
| JP (1) | JP7149854B2 (hu) |
| KR (1) | KR102472453B1 (hu) |
| CN (1) | CN109311875A (hu) |
| AU (1) | AU2017286379B2 (hu) |
| BR (1) | BR112018075999A2 (hu) |
| CA (1) | CA3025594A1 (hu) |
| DK (1) | DK3472160T3 (hu) |
| EA (1) | EA037361B1 (hu) |
| ES (1) | ES2871140T3 (hu) |
| HR (1) | HRP20210508T1 (hu) |
| HU (1) | HUE054118T2 (hu) |
| IL (1) | IL263652A (hu) |
| LT (1) | LT3472160T (hu) |
| MX (1) | MX2018015707A (hu) |
| SI (1) | SI3472160T1 (hu) |
| WO (1) | WO2017216292A1 (hu) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE061898T2 (hu) | 2017-09-08 | 2023-08-28 | Beigene Ltd | Imidazo[1,5-a]pirazin-származékok mint PI3Kdelta inhibitorok |
| CN111039946A (zh) * | 2018-10-15 | 2020-04-21 | 上海轶诺药业有限公司 | 一类咪唑并芳环类化合物的制备和应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090170848A1 (en) | 2006-03-02 | 2009-07-02 | Smithkline Beecham Corporation | Thiazolones for use as pi3 kinase inhibitors |
| JP2009544723A (ja) | 2006-07-24 | 2009-12-17 | スミスクライン・ビーチャム・コーポレイション | Ｐｉ３キナーゼ阻害剤としてのチオゾリジンジオン誘導体 |
| MX2009009031A (es) | 2007-02-22 | 2009-08-31 | Merck Serono Sa | Compuestos de quinoxalina y uso de los mismos. |
| JP2010535804A (ja) | 2007-08-09 | 2010-11-25 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Ｐｉ３キナーゼ阻害薬としてのキノキサリン誘導体 |
| AU2009204483B2 (en) | 2008-01-04 | 2014-03-13 | Intellikine, Llc | Certain chemical entities, compositions and methods |
| JP5576403B2 (ja) | 2009-02-06 | 2014-08-20 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | γ分泌酵素調節物質としての新規置換二環複素環化合物 |
| SG172898A1 (en) * | 2009-02-13 | 2011-08-29 | Bayer Schering Pharma Ag | Fused pyrimidines |
| EP2408773A2 (en) * | 2009-03-20 | 2012-01-25 | Amgen, Inc | Inhibitors of pi3 kinase |
| CA2771532C (en) | 2009-08-17 | 2021-03-23 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
| CA2775942A1 (en) | 2009-09-29 | 2011-04-07 | Xcovery Holding Company Llc | Pi3k (delta) selective inhibitors |
| DE102009052575A1 (de) | 2009-11-10 | 2011-05-12 | Siemens Medical Instruments Pte. Ltd. | Verfahren, Hörgerät und Anordnung zur Kalibrierung eines akustischen Anpasssystems |
| AR080754A1 (es) * | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
| UY33304A (es) | 2010-04-02 | 2011-10-31 | Amgen Inc | Compuestos heterocíclicos y sus usos |
| EA022623B1 (ru) | 2010-10-06 | 2016-02-29 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | Производные бензимидазола в качестве ингибиторов pi3-киназ |
| WO2012116237A2 (en) | 2011-02-23 | 2012-08-30 | Intellikine, Llc | Heterocyclic compounds and uses thereof |
| US9096605B2 (en) | 2011-08-24 | 2015-08-04 | Glaxosmithkline Llc | Pyrazolopyrimidine derivatives as PI3 kinase inhibitors |
| US8778937B2 (en) | 2011-12-20 | 2014-07-15 | Glaxosmithkline Llc | Benzimidazole boronic acid derivatives as PI3 kinase inhibitors |
| US8906910B2 (en) | 2011-12-20 | 2014-12-09 | Glaxosmithkline Llc | Imidazopyridine derivatives as PI3 kinase |
| EA028722B1 (ru) * | 2012-07-13 | 2017-12-29 | Юсб Байофарма Спрл | Производные имидазопиридина в качестве модуляторов активности tnf |
| GB201212513D0 (en) * | 2012-07-13 | 2012-08-29 | Ucb Pharma Sa | Therapeutic agents |
| TWI574962B (zh) * | 2012-11-14 | 2017-03-21 | 加拓科學公司 | 作爲ｐｉ３激酶調節劑的芳雜環化合物及其使用方法和用途 |
| AU2014336775B2 (en) * | 2013-10-16 | 2018-04-05 | Shanghai Yingli Pharmaceutical Co., Ltd | Fused heterocyclic compound, preparation method therefor, pharmaceutical composition, and uses thereof |
| HUE047382T2 (hu) | 2014-12-19 | 2020-04-28 | Janssen Pharmaceutica Nv | Heterociklus-kötött imidazopiridazin-származékok, mint PI3Kbéta-inhibitorok |
| ME03517B (me) | 2014-12-19 | 2020-04-20 | Janssen Pharmaceutica Nv | Derivati imidazopiridazina kao pi3kbeta inhibitori |
| JP6912460B2 (ja) | 2015-10-09 | 2021-08-04 | ヤンセン ファーマシューティカ エヌ．ベー． | ＰＩ３Ｋβ阻害剤としてのキノキサリンおよびピリドピラジン誘導体 |
-
2017
- 2017-06-15 CA CA3025594A patent/CA3025594A1/en active Pending
- 2017-06-15 AU AU2017286379A patent/AU2017286379B2/en active Active
- 2017-06-15 SI SI201730708T patent/SI3472160T1/sl unknown
- 2017-06-15 MX MX2018015707A patent/MX2018015707A/es active IP Right Grant
- 2017-06-15 CN CN201780037269.9A patent/CN109311875A/zh active Pending
- 2017-06-15 ES ES17732059T patent/ES2871140T3/es active Active
- 2017-06-15 EP EP17732059.5A patent/EP3472160B1/en active Active
- 2017-06-15 LT LTEP17732059.5T patent/LT3472160T/lt unknown
- 2017-06-15 JP JP2018564783A patent/JP7149854B2/ja active Active
- 2017-06-15 EA EA201990046A patent/EA037361B1/ru not_active IP Right Cessation
- 2017-06-15 KR KR1020187035198A patent/KR102472453B1/ko active IP Right Grant
- 2017-06-15 US US16/309,999 patent/US10894793B2/en active Active
- 2017-06-15 WO PCT/EP2017/064671 patent/WO2017216292A1/en unknown
- 2017-06-15 HU HUE17732059A patent/HUE054118T2/hu unknown
- 2017-06-15 DK DK17732059.5T patent/DK3472160T3/da active
- 2017-06-15 BR BR112018075999A patent/BR112018075999A2/pt unknown
-
2018
- 2018-12-11 IL IL263652A patent/IL263652A/en active IP Right Grant
-
2021
- 2021-03-30 HR HRP20210508TT patent/HRP20210508T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA037361B1 (ru) | 2021-03-18 |
| WO2017216292A1 (en) | 2017-12-21 |
| US20190169199A1 (en) | 2019-06-06 |
| JP7149854B2 (ja) | 2022-10-07 |
| CA3025594A1 (en) | 2017-12-21 |
| EA201990046A1 (ru) | 2019-05-31 |
| AU2017286379B2 (en) | 2021-07-01 |
| KR102472453B1 (ko) | 2022-11-29 |
| ES2871140T3 (es) | 2021-10-28 |
| KR20190016954A (ko) | 2019-02-19 |
| HRP20210508T1 (hr) | 2021-05-28 |
| US10894793B2 (en) | 2021-01-19 |
| LT3472160T (lt) | 2021-04-26 |
| JP2019518032A (ja) | 2019-06-27 |
| CN109311875A (zh) | 2019-02-05 |
| DK3472160T3 (da) | 2021-05-10 |
| BR112018075999A2 (pt) | 2019-04-02 |
| SI3472160T1 (sl) | 2021-07-30 |
| EP3472160A1 (en) | 2019-04-24 |
| MX2018015707A (es) | 2019-03-21 |
| IL263652A (en) | 2019-01-31 |
| EP3472160B1 (en) | 2021-02-24 |
| AU2017286379A1 (en) | 2018-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273756A (en) | Pyridines, pyrazines and triazines as inhibitors of allosteric shp2 | |
| HK1252752A1 (zh) | 新型吡唑並嘧啶衍生物 | |
| IL245345B (en) | History of pyridine, pyrimidine, pyrazine and pyridazine, their preparation and pharmaceutical preparations containing them | |
| IL243844B (en) | The history of pyridine, pyrimidine and pyrazine, their preparation and pharmaceutical preparations containing them | |
| IL254224A0 (en) | 7-substituted 5-alkyl-[4,2,1]triazolo[5,1-a]pyrimidine derivatives as pde2 inhibitors | |
| HK1217701A1 (zh) | -羥基- -吡唑- -基 煙酰胺衍生物和其用作 抑制劑 | |
| IL247947B (en) | 7,6,5,4-tetrahydro-pyrazolo[5,1-a]pyrazine compounds and 8,7,6,5-tetrahydro-h4-pyrazolo[5,1-a][4,1]diazepine compounds as ros1 inhibitors | |
| EP3313529A4 (en) | Fused bicyclic pyrimidine derivatives and uses thereof | |
| HK1251226A1 (zh) | 吡啶和嘧啶衍生物 | |
| IL248272B (en) | A new manufacturing process for triazine, pyrimidine and pyridine derivatives | |
| IL258707A (en) | 6-[5-amino-6-(2-ethoxyethoxy)-imidazo[4,5-b]pyridin-3-yl]-nicotinonitrile derivatives and their use as irak inhibitors | |
| HK1247192A1 (zh) | 吡啶或嘧啶衍生物 | |
| SI3196194T1 (sl) | Pirimidinski derivati, uporabni kot selektivni inhibitorji JAK3 in/ali JAK1 | |
| HK1253530A1 (zh) | 二氨基吡啶衍生物 | |
| IL263652A (en) | History of bicyclic pyridine, pyrazine, and pyrimidine as PI3K inhibitors in the cell | |
| IL258690A (en) | Pyridone derivatives and their use as kinase inhibitors |